天津医药 ›› 2017, Vol. 45 ›› Issue (7): 730-734.doi: 10.11958/20170129

• 临床研究 • 上一篇    下一篇

肺癌合并肺栓塞的影响因素及临床特征分析

李广生,李月川,马淑萍   

  1. 天津市胸科医院呼吸与危重症医学科 (邮编 300222)
  • 收稿日期:2017-01-25 修回日期:2017-05-14 出版日期:2017-07-15 发布日期:2017-08-08
  • 通讯作者: 李月川 E-mail:liyuechuandoctor@126.com

Analysis of risk factors and clinical characteristics of pulmonary embolism in patients with lung cancer

LI Guang-sheng,LI Yue-chuan,MA Shu-ping   

  1. Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, Tianjin 300222, China
  • Received:2017-01-25 Revised:2017-05-14 Published:2017-07-15 Online:2017-08-08
  • Contact: LI Yue-chuan E-mail:liyuechuandoctor@126.com

摘要: 目的 探讨肺癌伴发肺栓塞(PE)的影响因素、 临床特征及生存预后。方法 回顾性分析 2012 年 6 月— 2015 年 6 月于天津市胸科医院呼吸与危重症医学科确诊为肺癌伴 PE 的患者 28 例(合并 PE 组), 其中 11 例确诊PE 时有肺癌原发症状的加重或出现新发症状 (有症状组), 17 例患者为偶然发现、 无肺癌原发症状加重、 无新发症状(无症状组); 肺癌不伴 PE 患者 (无 PE 组) 56 例为对照。对合并 PE 组和无 PE 组病理类型及临床分期、 全身化疗、 白细胞 (WBC)、 血红蛋白 (Hb)、 血小板 (PLT)、 D-二聚体 (DD)、 白蛋白 (ALB)、 C 反应蛋白 (CRP) 行单因素分析, 对差异有统计学意义的指标进行 Logistic 回归分析观察影响因素。对合并 PE 组患者的栓塞影像形态和部位进行分析, 并分析有/无症状患者发生栓塞的中位时间及生存进展情况。结果 合并 PE 组腺癌比例、 全身化疗及Ⅲ+Ⅳ期比例高于无 PE 组 (P<0.01), WBC>11×109/L (高白细胞血症)、 ALB<30 g/L、 DD>0.5 mg/L 比例均高于无 PE 组 (P<0.05),其他指标包括临床症状差异无统计学意义; 腺癌、 全身化疗、 高白细胞血症、 DD>0.5 mg/L 为肺癌伴 PE 的独立危险因素 (P<0.05)。肺癌伴 PE 者中无症状性 PE 比例高, 其栓塞影像部位及形态与有症状性 PE 无差异, 无症状组栓塞发生中位时间 3.6 个月(95%CI: 3.2~4.0)早于有症状组的 10.5 个月(95%CI: 8.88~12.12), 差异有统计学意义(P<0.01), 无症状组 PE 中位生存时间 7.2 个月 (95%CI: 5.86~8.56) 长于有症状组的 2.8 个月 (95%CI: 2.48~3.12), 差异有统计学意义 (P<0.05)。结论 腺癌、 化疗、 高 WBC 血症、 DD>0.5 mg/L 是肺癌伴发 PE 危险因素, 无症状性 PE 发生率高, 栓塞发生时间更早、 预后更好。

关键词: 肺肿瘤, 肺栓塞, 危险因素, 生存时间

Abstract: Objective To investigate the risk factors, clinic charactertics and survival prognosis of pulmonary embolism (PE) in patients with lung cancer. Methods The clinic data of 28 lung cancer patients with PE, hospitalized in department of respiratory and critical care medicine of Tianjin Chest Hospital between June 2012 to June 2015, were retrospectively reviewed. Eleven of them were diagnosed with primary lung cancer and PE (symptomatic group), and 17 lung cancer patients were found PE accidentally (asymptomatic group). A total of 56 lung cancer patients without PE were used as control subjects (no PE group). Data of pathological types, clinical staging of lung cancer, systemic chemotherapy, white blood cell (WBC), hemoglobin (Hb), platelet (PLT), D- dimer (DD), albumin (ALB) and C- reactive protein (CRP) were analyzed by univariate analysis in the symptomatic group and asymptomatic group. Logistic regression analysis was carried out on the statistically significant indexes to observe the influencing factors. The morphology and location of the remobilization images were analyzed in lung cancer patients with PE. The median time to embolism and survival of PE patients were compared between symptomatic group and asymptomatic group. Results The proportion of adenocarcinoma,systemic chemotherapy and stage Ⅲ + Ⅳ were significantly higher in PE group than those in no PE group (P < 0.01). The ratio of white blood cells (WBC)> 11×109/L (hyperleukocytosis) and albumin (ALB) <30 g/L and D-dimer (DD)> 0.5 mg/L were significantly higher in PE group than those of no PE group (P < 0.05). There were no statistical differences in other indicators including clinical symptoms between the two groups (P > 0.05). The logistic regression analysis showed that adenocarcinoma, chemotherapy, WBC>11×109/L and DD>0.5 mg/L were the risk factors of lung cancer with PE (P < 0.05).There was higher ratio of asymptomatic PE in lung cancer patients with PE. There were no significant differences in morphology and location of the remobilization images in symptomatic group. The median time of embolization was 3.6 months(95% CI: 3.2- 4.0) in the asymptomatic group, which was significantly earlier than that in the symptomatic group (10.5months, 95% CI: 8.88-12.12, P < 0.01). The median survival time was 7.2 months (95% CI: 5.86-8.56) in the asymptomatic group, which was significantly longer than that of symptomatic group (2.8 months, 95% CI: 2.48- 3.12, P < 0.05).Conclusion Lung adenocarcinom, systemic chemotherapy, hypoproteinemia and increased D-dimer are the independent risk factors in lung cancer patients with PE. PE in lung cancer is frequently asymptomatic in the early stage. Compared to symptomatic patients, asymptomatic cases have better prognosis.

Key words: lung neoplasms, pulmonary thromboembolism, risk factors, survival time

中图分类号: